Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC).